The first generic raltegravir medications for treating adult and pediatric HIV patients weighing at least 40kg have been authorized by the UK Medicines and Healthcare products Regulatory Agency (MHRA). HIV is responsible for AIDS, which...
Renalys Pharma, Inc. reported the dosing of the initial participant in its phase III clinical trial of sparsentan for IgA nephropathy treatment in Japan. Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for the medication vibegron (Obgemsa) to address symptoms of overactive bladder (OAB) syndrome in adult patients. Indications might consist of a sudden...
The increasing prevalence of neurological disorders is fueling market expansion, as there is a shift towards manufacturing radiopharmaceuticals utilizing cyclotron technology. Yet, challenges arise due to issues with preparing and distributing...
Miltenyi Biotec, a prominent provider of biomedical solutions worldwide, has signed a Letter of Intent with the Translational Health Science and Technology Institute (THSTI) in New Delhi, an autonomous institute under the Department of...
Lupin, a global pharmaceutical company, announced a licensing and supply agreement with Huons, a top Korean pharmaceutical company to enhance their ophthalmology offerings. The focus of the agreement is on registering and marketing Cyclosporine...
Full-Life Technologies, a globally integrated radiotherapeutics company with facilities in Belgium, Germany, and China, has signed a $571.5 million license agreement with SK Biopharmaceuticals, a worldwide biotech company, for exclusive global...
Roche announced that another drug candidate acquired from Carmot Therapeutics showed positive results in an early trial, establishing the Swiss company as a strong competitor in the obesity drug development race. They reported in a statement that...
Mabwell, a cutting-edge biopharmaceutical company with full industry integration, revealed that its new Nectin-4 focused ADC (R&D code: 9MW2821) has been given the green light by the NMPA to move into phase II clinical testing as a standalone...
CordenPharma, a partner for CDMO services for biotech and pharma companies developing complex modalities, has revealed its most significant strategic investment of approximately €900 million in the next three years to expand its peptide technology...
, CDSCO.jpg)
